The agency named two ingredients — PABA and trolamine salicylate —
as not permitted for use in non-prescription sunscreen products,
adding that it is asking the industry for additional data on 12
other ingredients.
The health regulator said the proposed rule has been issued to
establish conditions under which some sunscreen drug products can be
sold without FDA-approved marketing applications.
The agency proposed that of the 16 currently used ingredients, only
two — zinc oxide and titanium dioxide — are considered safe and
effective based on available data.
In November 2016, the FDA had issued https://www.reuters.com/article/us-fda-sunscreen-idUSKBN13H1RE
guidelines detailing the data that makers of over-the-counter
sunscreens need to produce to prove the ingredients in the products
are safe and effective.
"Broad spectrum sunscreens with SPF values of at least 15 are
critical to the arsenal of tools for preventing skin cancer and
protecting the skin from damage caused by the sun's rays, yet some
of the essential requirements for these preventive tools haven't
been updated in decades," FDA Commissioner Scott Gottlieb said.
[to top of second column] |
Among other measures, the agency also plans to raise the maximum
proposed sun protection factor or SPF value on sunscreen labels from
SPF 50+ to SPF 60+.
SPF is a measure of the extent of protection a product offers
against the ultraviolet radiation in sun rays, that is generally
considered harmful.
Environmental Working Group (EWG), a nonprofit health and
environmental advocacy group, called the proposal a "big step toward
cleaning up a largely unregulated industry".
"We expect many companies to quickly reformulate to avoid those
ingredients that the FDA considers unsafe or for which there is not
enough data to prove safety," Scott Faber of EWG said on a press
call after FDA's announcement.
(Reporting by Manogna Maddipatla in Bengaluru; Editing by Shounak
Dasgupta)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |